Dendreon lowers expectations, touts DTC effort

Share this article:

Biotech Dendreon posted narrower second-quarter losses, logging a $69-million revenue shortfall for the quarter ended June 30, compared to $96 million for the same period last year. The net loss mirrored a dip in overall sales, which were $73 million for the quarter, compared to $80 million for the same period last year. As for a possible turnaround, management said the firm will not hit its year-over-year sales target.

Yet CEO John Johnson remains optimistic, because of 42 new accounts added in the quarter and because of increased consumer interest since initiation of a television DTC campaign March 7 for prostate cancer drug Provenge. The company said the TV ad serves a dual purpose: in addition to triggering calls into its phone centers, the spot also has unique dial-in numbers, helping the firm identify which channels are bringing in traffic.

 

The company could not share the patient conversion rates from caller to user, but management told investors during the August 8 earnings call that consumers need to see the ad about seven times before they are ready to dial in.

Johnson said the company's marketing efforts for Provenge have run into a few hurdles, with a key one being patients' lack of familiarity with immunotherapy. Marketing and awareness efforts are designed to explain the approach.

Dendreon is also looking to get a foothold in the pre-chemo space, so it can be used earlier in the treatment roster, and is considering sequencing studies with other prostate therapies, such as with the oral Astellas/Medivation drug Xtandi (enzalutemide) and with Janssen pill Zytiga (abiraterone acetate).

The company's sales efforts have focused on large accounts like community oncology centers, which provided about 38% of the business during the quarter, management said. Zytiga is posing stiff competition in smaller, low-volume accounts.
Share this article:

Email Newsletters

More in News

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Fabry disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.

Five things for pharma marketers to know: Wednesday, August 20

Five things for pharma marketers to know: Wednesday, ...

Novartis explores the virtual care space, a court has dismissed a lawsuit against IPAB, Doctors Without Borders calls the Ebola outbreak "a complete disaster" and Pfizer becomes the first pharma ...